Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Convertible Debt: 2014-2020

Historic Convertible Debt for Zevra Therapeutics (ZVRA) over the last 5 years, with Dec 2020 value amounting to $67.7 million.

  • Zevra Therapeutics' Convertible Debt fell 12.52% to $67.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $67.7 million, marking a year-over-year decrease of 12.52%. This contributed to the annual value of $67.7 million for FY2020, which is 12.52% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Convertible Debt of $67.7 million as of FY2020, which was down 12.52% from $77.3 million recorded in FY2019.
  • Zevra Therapeutics' 5-year Convertible Debt high stood at $78.1 million for FY2018, and its period low was $67.7 million during FY2020.
  • Its 3-year average for Convertible Debt is $74.4 million, with a median of $77.3 million in 2019.
  • Data for Zevra Therapeutics' Convertible Debt shows a maximum YoY fell of 12.52% (in 2020) over the last 5 years.
  • Zevra Therapeutics' Convertible Debt (Yearly) stood at $78.1 million in 2018, then declined by 0.98% to $77.3 million in 2019, then decreased by 12.52% to $67.7 million in 2020.